Fig. 3: Survival outcomes in patients treated with neoadjuvant Nivo+CT and Ipi+Nivo+CT. | Nature Medicine

Fig. 3: Survival outcomes in patients treated with neoadjuvant Nivo+CT and Ipi+Nivo+CT.

From: Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Fig. 3

a, Kaplan–Meier curve of EFS for the patients treated with neoadjuvant Nivo+CT (n = 22). Median EFS was not reached. Ten patients experienced recurrences 8.7 (died at 31.6 months), 17.7 (died at 20.0 months), 18.8 (died at 20.9 months), 19.5, 20.6, 21.7, 29.0, 30.4, 30.7 and 35.7 months after treatment initiation. b, Kaplan–Meier curve of OS for the patients treated with neoadjuvant Nivo+CT (n = 22). Median OS was not reached. Three patients died from complications related to recurrent lung cancer 20.0 months, 20.9 months and 31.6 months after treatment initiation. c, Kaplan–Meier curve of EFS for patients treated with neoadjuvant Ipi+Nivo+CT (n = 22). Median EFS was not reached. Four patients experienced recurrences 8.3, 8.6 (died at 26.7 months), 9.6 (died at 10.1 months) and 14.8 months after treatment initiation. *One patient died of SARS-CoV-2 infection-related complications (non-treatment related). d, Kaplan–Meier curve of OS for the patients treated with neoadjuvant Ipi+Nivo+CT (n = 22). Median OS was not reached. Two patients died from acute limb ischemia complications and lung cancer complications 10.1 months and 26.7 months after treatment initiation. *One patient died from SARS-CoV-2 infection-related complications (non-treatment related).

Back to article page